Maine Center for Disease Control and Prevention June 4, 2025 NOTIFIABLE DISEASES AND CONDITIONS LIST

Conditions are reportable **immediately** by telephone at 1-800-821-5821 (24 hours a day) on recognition or strong suspicion of disease All others are reportable by electronic lab report within **48 hours** of recognition or strong suspicion of disease

→ ▷ Directors of laboratories are to submit isolates or clinical specimens, as well as any isolates or clinical specimens as requested by Maine CDC, to the *Maine Health and Environmental Testing Laboratory* for confirmation, typing, and/or antibiotic sensitivity

Legionellosis Listeriosis ➔ ⊠ (<i>Listeria monocytogenes)</i>	Significance *See condition-specific footnotes on next p
Influenza-associated hospitalization, laboratory-confirmed	Any Cluster/Outbreak of Illness with Potential Public Health Any Cluster/Outbreak of Illness with Potential Public Health
Influenza A, Novel → ⊠	Any Case of Unusual Illness of Infectious Cause
Influenza-associated pediatric death	Zika
Human Immunodeficiency Virus (HIV) ⁸	Yellow Fever
Hepatitis B, C ⁷ , D (chronic)	Western Equine Encephalitis
Hepatitis A, B, C^7 , D, E (acute)	West Nile Virus 🗲 🖂
Hemolytic-uremic syndrome (post-diarrheal)	The second secon
Hard Tick Relapsing Fever (HTRF)	Vaping-associated pulmonary illness ⁹
Hantavirus, pulmonary and non-pulmonary syndromes → 🖂	<i>Vibrio</i> species, including Cholera ➔ ⊠ (<i>Vibrio</i> species)
Haemophilus influenzae, invasive → ⊠	Tularemia $\stackrel{'}{\rightarrow}$ 🖂 (<i>Francisella tularensis</i>)
Gonorrhea	tuberculosis)
Giardiasis	Tuberculosis (active and presumptive) → ⊠ (Mycobacterium
\rightarrow \boxtimes	Trichinosis
Enterococcus spp. resistant to linezolid and vancomycin (LVRE) ⁶	Tetanus → ⋈ (Clostridium tetani)
vancomycin (DLVRE) ⁵ $\rightarrow \square$	Syphilis
Enterococcus spp. resistant to daptomycin, linezolid, and	Streptococcus pneumoniae, invasive
Ehrlichiosis	Streptococcus Group A, invasive
Eastern Equine Encephalitis (EEE) → ⊠	only if MIC≥8µg/ml ⁶ → ⊠
E. coli, Shiga toxin-producing (STEC) $\rightarrow \boxtimes$	Staphylococcus aureus non-susceptible to Vancomycin (VRSA)
Dengue Diphtheria → ⊠ (Corynebacterium diphtheriae)	St. Louis Encephalitis
Dengue	Spotted Fever Rickettsiosis (SFR)
Cyclosporiasis	The smallpox \rightarrow ⊠ (Variola virus)
Cryptosporidiosis	Shigellosis → ⊠ (<i>Shigella</i> species)
Creutzfeldt-Jakob Disease (CJD), <55 years of age	Shellfish Poisoning
Coronavirus Disease 2019 (COVID-19)	Salmonellosis $\rightarrow \boxtimes$ (Salmonella species)
Coronavirus (Novel, MERS, and SARS) $\rightarrow \square$	
Chikungunya	
Chickenpox (Varicella)	🖀 Rabies (human and animal) 🗲 🖂 (Rabies virus)
Chlamydia	🖀 Q Fever
Chancroid	Psittacosis
Carbon monoxide poisoning ⁴	Powassan Virus → ⊠
Carbapenamase-Producing organisms ³ \rightarrow \boxtimes	Poliomyelitis → ⊠ (Polio virus)
Candida auris ² \rightarrow \boxtimes	
Campylobacteriosis	Pertussis
California Serogroup Virus Diseases → ⊠	serum ¹⁰
Brucellosis $\rightarrow \boxtimes$ (<i>Brucella</i> species)	Per and polyfluoroalkyl substances (PFAS) detectable in
Botulism → ⊠ (<i>Clostridium botulinum</i>)	Mumps → ⊠
Babesiosis	Mpox virus infection
Anthrax \rightarrow \boxtimes (<i>Bacillus anthracis</i>)	Meningococcal Disease, invasive → ⊠ (Neisseria meningitidis)
Anaplasmosis	
Acute flaccid myelitis (AFM) ¹	Malaria

Who must report: Health Care Providers, Medical Laboratories, Health Care Facilities, Child Care Facilities, Correctional Facilities, Educational Institutions, Administrators, Local Health Officers, Veterinarians, Veterinary Medical Laboratories **What to report:** Disease reports must include:

- Name of disease or condition and symptom onset
 - Name and phone number of person making the report and date
- Patient's name, date of birth, address, phone number, sex, race, and ethnicity
- Diagnostic laboratory findings and dates of test relevant to the notifiable condition
- Health care provider name, address, and phone number



Complete Rules for the Control of Notifiable Diseases and Conditions: www.maine.gov/dhhs/disease-reporting Maine Center for Disease Control and Prevention

NOTIFIABLE DISEASES AND CONDITIONS LIST Footnotes

- 1. An illness with an onset of acute focal limb weakness and either 1) cerebrospinal fluid with an elevated white blood cell count or 2) a magnetic resonance image (MRI) showing a spinal cord lesion largely restricted to gray matter and spanning one or more spinal segments.
- 2. Detection of *Candida auris* in a specimen using culture or culture independent diagnostic test; or detection of an organism that commonly represents a *Candida auris* misidentification.
- 3. Carbapenemase-producing carbapenem-resistant organisms are:
 - Carbapenem-resistant organisms, as defined by the Clinical Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing M100 (http://www.clsi-m100.com), that test positive for carbapenemase production by a phenotypic method or for one or more carbapenemase resistance mechanisms by a recognized test, as defined by the U.S. Centers for Disease Control and Prevention (https://wwwn.cdc.gov/nndss/conditions/carbapenemase-producing-carbapenem-resistantenterobacteriaceae/case-definition/2018/).
 - Reporting will include test method used, result, and where applicable, specific resistance mechanisms identified.
 - Isolate submission is required for all carbapenem-producing carbapenem-resistant organisms. If phenotypic or resistance mechanism test results are not available for a carbapenem-resistant organism, then isolate submission of the carbapenem-resistant organism is required to determine carbapenemase-producing status.
- 4. All cases with clinical signs, symptoms or known exposure consistent with diagnosis of carbon monoxide poisoning, and/or: a carboxyhemoglobin (COHb) level equal to or above 10%.
- 5. *Enterococcus* spp. resistant to daptomycin, linezolid, and vancomycin as defined by the most current Clinical Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing M100 (http://www.clsi-m100.com)
- 6. *Enterococcus* spp. resistant to linezolid and vancomycin as defined by the most current Clinical Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing M100 (http://www.clsi-m100.com)
- 7. Any hepatitis C virus (HCV) RNA test results, including:
 - All HCV RNA results (e.g. positive, negative, indeterminate, undetected for both qualitative and quantitative tests) including PCR, bDNA, TMA and Genotype.
 - In addition, Positive serology for anti-HCV (including signal-to-cut-off ratio for EIA, CIA, MEIA, or CMIA); Positive anti-HCV RIBA, and ALT >200 IU/L (in combination with one or more positive or detectable HCV result).
- 8. Any human immunodeficiency virus (HIV) test results, including:
 - All reactive/repeatedly reactive initial HIV immunoassay results and all results (e.g. positive, negative, indeterminate) from all supplemental HIV immunoassays (HIV-1/2 antibody differentiation assay, HIV-1 Western blot, HIV-2 Western blot or HIV-1 Immunofluorescent assay);
 - All HIV nucleic acid (RNA or DNA) detection tests (qualitative and quantitative), including tests on individual specimens for confirmation of nucleic acid amplification testing (NAAT) screening results;
 - All CD4 lymphocyte counts and percentages, unless known to be ordered for a condition other than HIV;
 - HIV genotypic resistance testing, nucleotide sequence results; and,
 - Positive HIV detection tests (including, but not limited to culture, P24 antigen).
- 9. Clinicians should report cases that meet the criteria of (1) a significant respiratory illness of unclear etiology and (2) a history of vaping.
- 10. Any serum test results from a venous blood sample that include a positive detection of:
 - Linear or branched perfluorooctanoic acid (PFOA);
- Perfluorononanoic acid (PFNA);
- Perfluorohexanesulfonic acid (PFHxS);
- Linear or branched perfluorooctanesulfonic acid (PFOS);
- Perfluoroheptanoic acid (PFHpA); or
- Perfluorodecanoic acid (PFDA).

If any PFAS is detected in a blood sample, the results for all PFAS testing of the sample must be reported to the Department.